Results 61 to 70 of about 1,809,097 (279)

Random Walks in Random Environment [PDF]

open access: yesJournal of Physics A: Mathematical and General, 2006
Random walks in random environments (RWRE's) have been a source of surprising phenomena and challenging problems since they began to be studied in the 70's. Hitting times and, more recently, certain regeneration structures, have played a major role in our understanding of RWRE's. We review these and provide some hints on current research directions and
openaire   +3 more sources

Random Walks and Spin Projections

open access: yesQuantum Reports
The purpose of this article is to highlight the connections between two seemingly distinct domains: random walks and the distribution of angular-momentum projections in quantum physics (the magnetic quantum numbers m).
Jean-Christophe Pain
doaj   +1 more source

Field theories for loop-erased random walks

open access: yesNuclear Physics B, 2019
Self-avoiding walks (SAWs) and loop-erased random walks (LERWs) are two ensembles of random paths with numerous applications in mathematics, statistical physics and quantum field theory.
Kay Jörg Wiese, Andrei A. Fedorenko
doaj   +1 more source

Directivity of Quantum Walk via Its Random Walk Replica

open access: yesComplexity, 2022
Quantum walks (QWs) exhibit different properties compared with classical random walks (RWs), most notably by linear spreading and localization. In the meantime, random walks that replicate quantum walks, which we refer to as quantum-walk-replicating ...
Tomoki Yamagami   +5 more
doaj   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

open access: yesMolecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura   +19 more
wiley   +1 more source

USP29‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer

open access: yesMolecular Oncology, EarlyView.
We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober   +16 more
wiley   +1 more source

Large Deviations for Continuous Time Random Walks

open access: yesEntropy, 2020
Recently observation of random walks in complex environments like the cell and other glassy systems revealed that the spreading of particles, at its tails, follows a spatial exponential decay instead of the canonical Gaussian.
Wanli Wang, Eli Barkai, Stanislav Burov
doaj   +1 more source

Cancer‐associated mutations in endometriosis reframe a benign disease through molecular oncology

open access: yesMolecular Oncology, EarlyView.
This review aims to comprehensively analyse cancer‐associated somatic mutations (CAMs) present in endometriotic lesions, emphasizing their biological roles, spatial distribution and implications for translational applications in medicine. By contextualizing a benign state within a genomic framework, this analysis seeks to establish its value as a ...
Clarissa Mujacic   +15 more
wiley   +1 more source

Generalized (c,d)-Entropy and Aging Random Walks

open access: yesEntropy, 2013
Complex systems are often inherently non-ergodic and non-Markovian and Shannon entropy loses its applicability. Accelerating, path-dependent and aging random walks offer an intuitive picture for non-ergodic and non-Markovian systems.
Rudolf Hanel, Stefan Thurner
doaj   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

open access: yesMolecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy